Vicuron Will Resubmit Anidulafungin For Invasive Candidiasis Under Separate NDA

Current NDA will focus on esophageal candidiasis indication; Vicuron plans to submit an amendment in second quarter 2005 to address FDA’s concerns about the “approvable” antifungal. Invasive candidiasis NDA filing is slated for third quarter 2005.